A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  • Ghali, Joanna (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date21/07/22 → 20/07/27

Keywords

  • phase 2 study
  • Randomised clinical trial
  • lupus nephritis
  • treatment efficacy
  • treatment safety